Mark Benjamin Email and Phone Number
Mark Benjamin work email
- Valid
- Valid
- Valid
Mark Benjamin personal email
Mark Benjamin phone numbers
INNOVATIVE BIOTECHNOLOGY EXECUTIVE DRIVING VISION AND DEVELOPING ORGANIZATIONS FOR BUSINESS GROWTH. A biotech industry executive leading strategic planning, business development, financing, and team development (both scientific and operational) that result in revenue-generating opportunities to maximize the value and success of innovative technology start-up companies. An influential and persuasive negotiator who effectively communicates the company's technology, value and direction to diverse stakeholders, resulting in strategic partnerships and high-value deals with customers, collaborators and investors. A transformational leader, I bring organizational structure, solid leadership that promotes a cooperative and creative culture, and process optimization expertise to rapidly evolving business environments.With a Harvard Doctorate of Science degree combined with a career that began in research, I developed a unique talent for translating and articulating complex science and technology into compelling business propositions understood by diverse audiences. In addition, my business experience has enabled me to develop keen cultural sensitivity/understanding critical to nurture relationships and bridge communications for conducting business and negotiating partnerships with European and Asian companies. Competitive Assets:♦ Corporate Strategy Planning♦ Business Development♦ Financing | Private Equity♦ Product / Asset Commercialization♦ P&L Management♦ External Communications♦ Value Creation♦ Organizational Development♦ International Business Negotiations♦ Contract Negotiations♦ Partnership / Collaboration Agreements♦ Performance Management♦ Team Building and Management
-
President & Evp Business DevelopmentCyrus Biotechnology Oct 2019 - PresentSeattle, Washington, UsProtein engineering and structure prediction, based on the Rosetta computational engine out of the UW lab of David Baker, directed at a new generation of protein therapeutics.
-
OwnerMbb Consulting Llc Jan 2018 - PresentConsulting to the biotechnology industry with an emphasis on startup company and new initiatives development.Providing advice and mentoring to young companies, focused on strategic planning, business development, partnering, negotiations, fund-raising, communications, leadership and management.
-
Advisor - Business DevelopmentSimcere Pharmaceutical Group Jan 2019 - Mar 2020南京市玄武区, 江苏, Cn -
Advisor - Business DevelopmentPhosphorex Oct 2018 - Mar 2020Hopkinton, Ma, Us -
Chief Business OfficerQ-State Biosciences Nov 2016 - Dec 2017Cambridge, Ma, UsLead business development operations, following Q-State's acquisition of Galenea. Helped refocus business development activities from multiple small technology-validating collaborations to high value partnerships, leading the negotiation of highly lucrative collaborations, including a multi-year drug discovery partnership with Vertex Pharmaceuticals. Represented the company in external communications with the media, public disclosures and related activities. -
President & Ceo | Board MemberGalenea Corp. 2007 - 2016Established the structure and a commercial vision for the discovery corporation, operating within a multi-year partnership with Otsuka Pharmaceuticals (OTSKZ: JP, Tokyo, Japan). Managed P&L and a 50+ employee organization in cutting-edge neuroscience R&D. Instituted a matrixed organizational structure for more efficient achievement of drug discovery objectives, dramatically improving productivity and strengthening Otsuka relationship. Led the re-negotiation of a complex multi-year partnership between Galenea and Otsuka Pharmaceuticals, which provided Galenea with financing to build a significant chemistry capability, obtaining critical technology ownership rights, which in turn enabled three new pharma deals, ensuring extended business viability. Negotiated two extensions and expansions of the initial collaboration from a five-year agreement/$50M term to a seven-year/$90M conclusion, as well as the acquisition of two assets, one clinic stage.
-
Chief Business OfficerNura 2004 - 2006Recruited to help rebuild Nura's organizational structure and promote viability of the commercial plan for the CNS therapeutics discovery company. As member of the operations management team, oversaw Operations and Human Resources. Involved in fundraising, establishing licensing agreements and developing revenue-generating collaborations. Secured access to candidate pharmaceuticals and chemical libraries at Nura, Inc. through partnerships with technology providers in the US and Singapore. Played an instrumental role in securing company's $10M series A financing, which involved dialogue with a syndicate of venture groups, including Vulcan Ventures, Microsoft co-founder Paul Allen's venture firm. Company was acquired in 2006 by Omeros (NASD: OMER)
-
Irb Member And Chairman Pro-TemUniversity Of Washington 2004 - 2006Seattle, Wa, Us -
President, Us Operations | Vp, Global Business Development | Board MemberManteia Predictive Medicine 2001 - 2003Brought on board following the Swiss-based biotech company's formation to establish vision and strategy and to position DNA sequencing technology for the consumer market. Directed business development efforts in the US and Europe, including in-licensing of intellectual property, opportunity evaluation, service and research collaboration negotiation, and fundraising. Chosen to launch and manage US operations in 2001. Company's research focused on the development of a novel ultra-high throughput DNA sequencing technology for application in the field of predictive medicine, which was sold and ultimately incorporated into the Illumina (NASD: ILMN) DNA sequencing platform.
-
Sr. Director, Business DevelopmentRosetta Inpharmatics 1999 - 2001Seattle, Washington, UsRecruited by the company President to initiate, negotiate, and manage corporate alliances and create revenue-generating alliances in the pharmaceutical, biotechnology and agrigenomics industries. Built business development team, created commercialization plans for the technology, identified target companies, and developed relationships with lead scientists, clinicians, and business development teams within targeted companies. Executed high-value collaborations with pharma and ag-bio companies, out-licensed Rosetta microarray technology and developed a critical supply agreement with Agilent Technologies which contributed to Rosetta's competitive advantage and ultimate sale to Merck & Co. (NYSE: MRK) in 2001. -
Vp Business DevelopmentXenometrix 1997 - 1999Promoted to apply communications strengths in a dedicated business development role at the former pharmacogenomics company. Attended and presented research at industry conferences and collaborated with biotechnology companies to determine ways in which Xenometrix technologycould be applied to business strategy or product development. Raised several million dollars to sustain ongoing research by devising and launching a program, which sought licensees based on the potential for Xenometrix's IP to impact emerging companies.
-
Director Of Scientific AffairsXenometrix 1994 - 1997Developed and executed communications strategy to showcase research value to the biotechnology community. Negotiated the company's partnerships and collaborations.
-
Director Of ResearchXenometrix 1992 - 1994Managed a team of nine in multiple research programs in the company. Presented research topics and opportunities for collaboration to potential partners.Initially recruited as a Project Leader and Associate Laboratory Director (1992 - 1993) based on patent developed as a Postdoctoral Fellow at Harvard Medical School.
Mark Benjamin Skills
Mark Benjamin Education Details
-
Harvard UniversityCancer Biology -
University Of LondonGenetics & Microbiology
Frequently Asked Questions about Mark Benjamin
What company does Mark Benjamin work for?
Mark Benjamin works for Cyrus Biotechnology
What is Mark Benjamin's role at the current company?
Mark Benjamin's current role is President & EVP Business Development at Cyrus Biotechnology.
What is Mark Benjamin's email address?
Mark Benjamin's email address is mb****@****nea.com
What is Mark Benjamin's direct phone number?
Mark Benjamin's direct phone number is +161737*****
What schools did Mark Benjamin attend?
Mark Benjamin attended Harvard University, University Of London.
What skills is Mark Benjamin known for?
Mark Benjamin has skills like Business Development, Clinical Trials, Cancer, Lifesciences, Biotechnology, Drug Discovery, Biochemistry, Drug Development, Protein Chemistry, Oncology, Pharmaceutical Industry, Technology Transfer.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial